Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update

The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs beco...

Full description

Saved in:
Bibliographic Details
Published inHepatology research Vol. 50; no. 8; pp. 892 - 923
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc 01.08.2020
Subjects
antiviral treatment
drug resistance
Hepatitis B
hepatocellular carcinoma
Hepatology
Management
Tenofovir
tenofovir alafenamide
tenofovir disoproxil fumarate
Japan
Online AccessGet full text

Cover

More Information
Summary:The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug‐resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.
Bibliography:Drafting Committee for Hepatitis Management Guidelines (in alphabetical order): Ryoichi Ando, Department of Nephrology, Musashino Red Cross Hospital (appointed by the Japanese Society for Dialysis Therapy); Yasuhiro Asahina, Department of Gastroenterology and Hepatology, School of Medicine/Department of Liver Disease Control, Graduate School of Medical and Dental Sciences; Tokyo Medical and Dental University; Kazuaki Chayama*, Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University Naoki Hiramatsu Department of Gastroenterology, Osaka Rosai Hospital; Toru Ikegami Department of Surgery and Science, Kyushu University; Namiki Izumi, Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital; Kan Kikuchi, Department of Nephrology, Shimoochiai Clinic (appointed by the Japanese Society for Dialysis Therapy); Kazuhiko Koike Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo Masayuki Kurosaki Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital; Satoshi Mochida Department of Gastroenterology and Hepatology, Saitama Medical University; Fumitaka Suzuki,Department ofHepatology, Toranomon Hospital; Tetsuo Takehara*, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine; Hajime Takikawa**, Department of Medicine, Teikyo University School of Medicine; Atsushi Tanaka, Department of Medicine, Teikyo University School of Medicine Eiji Tanaka Department for the Promotion of Regional Medicine, Shinshu University School of Medicine; Yasuhito Tanaka, Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences; Hiroshi Yotsuyanagi, Department of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo (*Special Committee Member; **Committee Chair)
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.13504